Becketts advises Telix Pharmaceuticals on acquisition of QSAM Biosciences, Inc. (U.S.)

Telix is an ASX-listed (ASX: TLX) biopharmaceuticals company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe and Japan.

QSAM is a United States based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer. QSAM’s primary asset is its lead investigational drug Samarium‑153‑DOTMP. The acquisition is designed to be a complementary and early commercial entry-point for Telix’s prostate cancer therapy franchise.

The Becketts team which advised Telix on the transaction included Alex Bean and Nick Golding, Partners, and Brad Papaluca, Lawyer. Telix’s US lawyers on the transaction were Wilmer Hale, with the team led by Judd Abramson, Counsel and Ashton Kennedy, Associate.